COHBAR, INC.
COHBAR, INC. (COBU): 3 pipeline candidates · ~20 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
20.1 months
D/E 0.32 · 0% dilution
Lead: Phase 1
3 candidates
N/A
N/A
A transparent, data-derived signal for COHBAR, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$6.2M
Quarterly Burn
$1.8M
Runway
20.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| cb4211 | Phase 1 |
| cb5064 analogs | Preclinical |
| cb5138-3 | Preclinical |
Frequently asked questions
How many drug candidates are in COHBAR, INC.'s pipeline?
COHBAR, INC. (COBU) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is COHBAR, INC.'s lead drug candidate?
COHBAR, INC.'s most advanced tracked candidate is cb4211 (Phase 1) for NASH and obesity.
What is COHBAR, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, COHBAR, INC. has approximately 20.1 months of cash runway.
Who is the CEO of COHBAR, INC.?
Geron Corporation is the chief executive officer of COHBAR, INC. (COBU).
Get the full picture on COHBAR, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.